Game-changing cancer therapy: Imugene’s VAXINIA receives FDA orphan drug status for bile tract cancer
Imugene Limited has received a significant boost with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its experimental therapy, ... Read More
New data from Incyte highlights efficacy of CDK2 inhibitor in ovarian cancer; Pivotal trials expected in 2025
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing promising results in patients with advanced solid ... Read More
Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination ... Read More
Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program ... Read More
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More
Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication ... Read More
Ascentage Pharma receives $100m payment from Takeda under exclusive option agreement
Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has announced the receipt of a US$100 million ... Read More
Signet Therapeutics gets FDA IND approval for sigx1094 in diffuse gastric cancer
Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)'s Investigational New Drug (IND) approval of ... Read More
Exploring Marine Cytotoxic Compounds in Cancer Treatment
Marine organisms offer a vast reservoir of cytotoxic compounds with potential therapeutic applications in treating various cancers. These biomedicines, known as marine drugs, are derived ... Read More